The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...

After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS ...

JT Lew, PharmD, MBA, managed care pharmacist at MultiCare Health System, spoke to the impacts of processes such as prior authorization and step therapy requirements in the realm of multiple sclerosis ...

Confirmed six-month disability progression rates over 4 years were similar in patients given the oral statin or a placebo in ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

[5] Pinke KH, et al. Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? Neurotherapeutics. 2020 Jan;17(1):218-234. [6] Brown MA, Weinberg RB. Mast Cells and ...

New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...

Rich nations hold millions of mpox vaccines as Africa grapples with an outbreak, while the US FDA approves Roche's multiple ...

The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...

A pharmaceutical and a nonprofit are teaming up to evaluate segesterone acetate as a possible MS therapy to restore lost myelin in patients.

New research highlights the benefits of starting monoclonal antibody therapy for multiple sclerosis in childhood. The study, ...

The study, which utilised data from the French MS Registry, Italian MS Register, and the global MSBase Registry, analysed the outcomes of 282 patients with paediatric-onset MS.